Mark R. Hake

Mark R. Hake

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

Expect MGM Stock to Move Higher This Year as Gambling Rebounds

Expect MGM stock to move higher this year. MGM stock is worth between $47.05 and $50.72, which is more than several analysts project.

Delta Air Lines Stock Will Soar When Free Cash Flow Turns Positive

Delta Air Lines stock will Soar when free cash flow turns positive. DAL stock is worth at least $73.90 or 48% more, assuming low FCF margins by 2022.

Plug Power Stock Reflects All The Upside With Its High Valuation

Plug Power stock reflects all the upside with its high valuation. PLUG stock is simply too expensive at 38 times sales forecast for 2021.

Organigram Is Another Losing Cannabis Stock To Avoid

Organigram is just another money-losing Canadian cannabis company. OGI stock is nowhere near profitability, so most investors should avoid it.

iBio Stock Is Not Likely To Move Higher Given Its Huge Dilution

IBIO stock is not likely to move higher given its huge dilution. I think it is not worth more than 48 cents per share.